New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
17:02 EDTSQNMSequenom CMM's announces results of RetnaGene AMD
Sequenom announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine, presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago. This Sequenom CMM laboratory-developed genetic test combines patient disease stage with patient genetic variation to evaluate the risk of a patient with early or intermediate AMD to progress to advanced choroidal neovascularization, or CNV, disease within 2, 5, and 10 years. CNV is the most common form of 'wet' advanced age-related macular degeneration, or AMD, in which new blood vessels in the eye leak fluid, compromising central vision. Advanced disease impacts approximately 10% of AMD patients, but is associated with 90 percent of vision loss in AMD.
News For SQNM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
16:40 EDTSQNMSequenom files $300M mixed securities shelf
Subscribe for More Information
August 25, 2015
17:32 EDTSQNMSequenom enters collaboration with UC San Diego Moores Cancer Center
Subscribe for More Information
August 24, 2015
08:29 EDTSQNMWilliam Blair to hold a field trip
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use